Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Ms. Dominique Rmy-Renou

Market Cap

2.48 Million EUR

Sector

Healthcare

Website

https://www.genomicvision.com

Description

Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France.

Read More

Overview

Value

1

Growth

62

Health

23

Management

60

Analyst Opinion

63

Total

42

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Earnings growth has improved recently
  • Has a low level of debt
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Income is not covering expenditure and investment
  • Earnings are negative
  • There is a history of diluting shareholders
  • Altman-Z score suggests a risk of bankruptcy
  • Poor overall financial health
  • No margin of safety at their current market price
  • Cashflow is growing faster than revenue

Market Peers

GV.PA

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-156.81%

Revenue Growth (5 Year Average)

12.23%

Ratings Consensus

Neutral

Share Buybacks

-80.93%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

1

  • Estimated intrinsic-value of NaN undefined EUR is lower than current price ( 23.80 undefined EUR)
  • Free-cashflow-yeild of -179.81% is worse than the market average (4.7%)
  • Margin-of-safety of -156.81% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 0 EUR

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-179.81%

PE/Earnings Growth

N/A

Price/Book

6.08x

Growth

Growth Score

62

  • 5 Year Average Revenue growth of 12.23% is higher than the market average (10.97%)
  • 5 Year Average Earnings growth of 21.41% is higher than the market average (14.48%)
  • Earnings growth has improved this year
  • Free Cashflow growth has improved this year
  • Revenue growth has slowed this year
  • 5 Year Average Free Cashflow growth of 13.17% is lower than the market average (12.35%)

Revenue Growth

12.23%

Earnings Growth

21.41%

Cashflow Growth

13.17%

Health

Health Score

23

  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Altman-Z score suggests a risk of bankruptcy
  • Debt repayments significantly impact cashflow

Altman Z Score

-3.31

Piostroski Score

1.00

Debt/Equity

0.32x

Current Assets/Liabilities

2.01x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

0.19x

Management

Management Score

60

  • Has issued new shares to finance growth when share price is high
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -323.58% is lower than the market average (15%)
  • Return-on-capital-employed of -47.19% is lower than the market average (10%)

Average Buybacks/Dilution

-80.93%

Recent Buybacks/Dilution

97.54%

5 Year Price Volitility

95.34%

Return On Assets

-146.66%

Return On Capital Employed

-47.19%

Return On Equity

-323.58%

Return On Free Cashflow

260.71%

Return On Investments

N/A

Analysts

Analyst Opinion

63

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Genomic Vision Société Anonyme

Currency

EUR

Beta

-0.294901

Vol Avg

2709759

Ceo

Ms. Dominique Rmy-Renou

Cik

Cusip

Exchange

Paris

Full Time Employees

33

Industry

Diagnostics & Research

Sector

Healthcare

Ipo Date

2014-04-02

Address

Green Square Batiment E, 80-84 rue des Meuniers

City

Bagneux

State

ILE-DE-FRANCE

Country

FR

Zip

92220

Phone

33149080740

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies